A new meta‑analysis aggregated clinical data comparing CAR‑T cell therapies and bispecific antibody treatments in relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphoma. The study performs a head‑to‑head synthesis of response rates, durability and safety signals to inform treatment selection where both modalities are available. CAR‑T and bispecifics represent distinct immunotherapy approaches—autologous engineered T cells versus bispecific proteins that recruit T cells to tumor cells—and this comparative review highlights tradeoffs in logistic complexity, toxicity profiles and remission durability that hospital systems and biopharma teams must weigh when building treatment pathways.